CeQur Raises Significant Series E Funding
CeQur, based in Horw, Switzerland, has successfully secured $100 million in its Series E funding round, announced on June 9, 2026. The company is known for its innovative approach to diabetes management with the CeQur Simplicity, a 4-day injection-free wearable mealtime insulin patch designed to eliminate the need for multiple daily insulin injections.
Leadership and Vision
Under the leadership of President and CEO Bradley Paddock, CeQur is poised to expand its market presence and further develop its product offerings. Paddock's vision for the company is centered around improving the quality of life for individuals with diabetes by providing a user-friendly and effective alternative to traditional insulin delivery methods.
Strategic Use of Funds
While specific investors in this round have not been disclosed, the substantial funding will be directed towards several key areas of growth and development. The primary focus will be on enhancing the current product line and expanding the reach of CeQur Simplicity in new and existing markets.
Future Developments
CeQur plans to leverage this significant financial boost to scale its operations and improve product accessibility. The company's commitment to innovation in diabetes care is expected to drive further advancements in its wearable insulin delivery technology.
With this latest round of funding, CeQur is well-positioned to continue its mission of transforming diabetes management and offering patients a more convenient and less invasive option for insulin delivery.